August 4, 2021 -- Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year.
For the second quarter of 2021, the company reported revenue of $914.6 million. During the same quarter in 2020, company revenue was $682.6 million. Acquisitions, the impact of foreign currency translation, and contributions from Charles River's three business segments were attributed to the revenue growth.
Revenue from the Manufacturing Solutions segment spiked 60% from $123.5 million in the second quarter of 2020 to $197.8 million during the same period of 2021. Approximately 28% of revenue in this segment was attributed to the acquisition of Cognate BioServices, according to the company.
The Research Models and Services segment brought in $176.7 million in revenue in the second quarter. This was a 51.6% increase from the segment's $116.5 million in revenue generated in the second quarter of 2020. Finally, revenue from the Discovery and Safety Assessment segment rose 22% from $442.6 million in the second quarter of 2020 to $540.1 million in the same quarter of 2021.
Based on the company's strong second-quarter financial performance, Charles River is boosting its forecast for 2021. It expects to achieve 2021 revenue growth of 20.5% to 22.5%, an increase from the previous projected growth of 19% to 21%.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
